Methods of treating relapsing multiple sclerosis using fenebrutinib 200mg twice daily
Summary
USPTO issued Patent US12605376B2 to Genentech, Inc. covering methods of treating Relapsing Multiple Sclerosis using fenebrutinib, a Bruton's tyrosine kinase inhibitor. The patent protects administration of approximately 200 mg of fenebrutinib twice daily, or an equivalent amount of a pharmaceutically acceptable salt thereof. The patent contains 17 claims and is classified under CPC codes A61K 31/4985, A61P 37/00, and A61P 25/00.
“Provided herein are methods of treating Relapsing Multiple Sclerosis (RMS) in a subject in need thereof, by administering to the subject about 200 mg of fenebrutinib twice daily, or an equivalent amount of a pharmaceutically acceptable salt thereof.”
What changed
USPTO granted Patent US12605376B2 to Genentech, Inc. on April 21, 2026. The patent covers methods of treating Relapsing Multiple Sclerosis by administering 200 mg of fenebrutinib twice daily, with the application filed on April 1, 2021 under application number 17995259. The patent contains 17 claims and names Hideki Garren, Edmond Huatung Teng, Aurelien Viaccoz, and Hans-Christian Von Buedingen as inventors.\n\nPharmaceutical manufacturers developing or marketing BTK inhibitors for neurological conditions should review this patent to assess potential freedom-to-operate implications for their programs. Healthcare providers and clinical investigators studying MS treatments may also find the disclosed dosing regimen relevant to trial design and treatment protocols.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods of treating relapsing multiple sclerosis using an inhibitor of Bruton's tyrosine kinase
Grant US12605376B2 Kind: B2 Apr 21, 2026
Assignee
Genentech, Inc.
Inventors
Hideki Garren, Edmond Huatung Teng, Aurelien Viaccoz, Hans-Christian Von Buedingen
Abstract
Provided herein are methods of treating Relapsing Multiple Sclerosis (RMS) in a subject in need thereof, by administering to the subject about 200 mg of fenebrutinib twice daily, or an equivalent amount of a pharmaceutically acceptable salt thereof.
CPC Classifications
A61K 31/4985 A61P 37/00 A61P 25/00
Filing Date
2021-04-01
Application No.
17995259
Claims
17
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.